Financials in USD. Standardized financial statements.
A compact view of how CG Oncology, Inc. Common stock turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue? | $4.04M | $1.14M | $204,000 | $191,000 | $10.36M |
| Revenue Growth? | +254.7% | +458.3% | +6.8% | -98.2% | 0.0% |
| Cost of Revenue? | $4.65M | $0 | $0 | $15,000 | $10,000 |
| Gross Profit? | -$607,000 | $1.14M | $204,000 | $176,000 | $10.35M |
| Gross Margin? | -15.0% | +100.0% | +100.0% | +92.1% | +99.9% |
| Operating Expenses? | $190.17M | $115.81M | $55.65M | $35.42M | $22.95M |
| Operating Income? | -$190.77M | -$114.67M | -$55.45M | -$35.25M | -$12.61M |
| EBITDA? | -$159.55M | -$114.63M | -$55.43M | -$35.23M | -$12.38M |
| Income Before Tax | -$161.00M | -$88.04M | -$48.61M | -$35.44M | -$12.84M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$161.00M | -$88.04M | -$48.61M | -$35.44M | -$12.84M |
| EPS? | $-2.08 | $-1.41 | $-1.02 | $-0.66 | $-0.28 |
| Diluted EPS? | $-2.08 | $-1.41 | $-1.02 | $-0.66 | $-0.28 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality